Dépôt numérique

Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity


Téléchargements par mois depuis la dernière année

Plus de statistiques...

Dagenais-Lussier, Xavier; Loucif, Hamza; Murira, Armstrong; Laulhe, Xavier; Stäger, Simona; Lamarre, Alain et van Grevenynghe, Julien ORCID logoORCID: https://orcid.org/0000-0002-2952-4081 (2017). Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity Viruses , vol. 10 , nº 1: 12. pp. 1-11. DOI: 10.3390/v10010012.

[thumbnail of Dagenais-Lussier 2017-Sustained IFN-I Expression during Established Persistent Viral Infection- A Bad Seed for Protective Immunity.pdf]
PDF - Version publiée
Disponible sous licence Creative Commons Attribution.

Télécharger (4MB) | Prévisualisation


Type I interferons (IFN-I) are one of the primary immune defenses against viruses. Similar to all other molecular mechanisms that are central to eliciting protective immune responses, IFN-I expression is subject to homeostatic controls that regulate cytokine levels upon clearing the infection. However, in the case of established persistent viral infection, sustained elevation of IFN-I expression bears deleterious effects to the host and is today considered as the major driver of inflammation and immunosuppression. In fact, numerous emerging studies place sustained IFN-I expression as a common nexus in the pathogenesis of multiple chronic diseases including persistent infections with the human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV), as well as the rodent-borne lymphocytic choriomeningitis virus clone 13 (LCMV clone 13). In this review, we highlight recent studies illustrating the molecular dysregulation and resultant cellular dysfunction in both innate and adaptive immune responses driven by sustained IFN-I expression. Here, we place particular emphasis on the efficacy of IFN-I receptor (IFNR) blockade towards improving immune responses against viral infections given the emerging therapeutic approach of blocking IFNR using neutralizing antibodies (Abs) in chronically infected patients.

Type de document: Article
Mots-clés libres: -
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 22 mars 2019 15:10
Dernière modification: 16 févr. 2022 15:44
URI: https://espace.inrs.ca/id/eprint/6714

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice